CommercialCoverageMedium impact
11.08.17l, Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toenails
Independence Blue Cross·Podiatry, Dermatology, Family Medicine·Medical Policy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
IBX Commercial has updated their medical policy for debridement of mycotic and symptomatic non-mycotic hypertrophic toenails, effective October 1, 2025. This policy change affects coverage and billing guidelines for toenail debridement procedures under commercial insurance plans.
Action Required
By October 1, 2025: Billing team must review and implement updated IBX Commercial policy guidelines for toenail debridement procedures. Access the full policy details at the provided URL to understand specific coverage criteria and documentation requirements. Update billing protocols and inform providers of any changes to ensure compliant claims submission.